SecBot SecBot

RFL

Rafael Holdings, Inc.
NYSE· Pharmaceutical Preparations· Inc. DE· CIK 0001713863 Biotech & Drug Discovery
$1.18 −0.13 (−9.92%)
Oct 26 4:00 PM ET · prev $1.31
Market cap
$66.6M
Micro cap
Next earnings
Nov 2
in 7 days
1 year
−12.6%
from $1.35 · Oct 27
30 days
−41.6%
from $2.02
52-week range
$1.16–3.78
−69% from high · low Jan 30
Avg volume 20D
205.7K
Sep 30 spike 2.29M
Short interest
🔒 Subscribers only
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
5
analyzed by SecBot
SecBot read MIXED 3 reports · 90 days
Balance 0 bearish · 1 bullish · 2 mixed oldest → newest, height = score
Avg score ·High conf. 1/3 ·Next Earnings date, Nov 2, 2026
Strongest MIXED Rafael Holdings announced topline results from its pivotal Phase 3 TransportNPC study of Trappsol Cyclo in…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBULLISH

    Q2 2026: 8 added (0 new), 2 trimmed or exited.

  • TrendDOWNTREND

    37% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
STATE STREET CORPDOUBLED157,270$515.8K
KAHN BROTHERS GROUP INCDOUBLED150,493$493.6K
JANE STREET GROUP, LLCDOUBLED112,720$369.7K
SUSQUEHANNA INTERNATIONAL GROUP, LLPDOUBLED70,673$231.8K
RENAISSANCE TECHNOLOGIES LLCTRIM59,815$196.2K
CITADEL ADVISORS LLCDOUBLED49,122$161.1K
MORGAN STANLEYADD12,334$40.5K
SIMPLEX TRADING, LLCDOUBLED12,082$39.6K

Quarterly 13F filings are due 45 days after each quarter ends.

Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 2, 2026
Earnings date
RFL Q4 2026 Earnings Scheduled — 2026-11-02
Recent
Oct 15, 2026
Press release
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFL
NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rafael Holdings, Inc. ("Rafael" or the…
Sep 30, 2026
FDA
Rafael Holdings Announces Topline Results from the Pivotal Phase 3 TransportNPC™ Study of Trappsol® Cyclo™ in Niemann-Pick Disease Type C (NPC)
Please post to IR news on company website and send to excel distribution list on file. Thank you. Best, Barbara
Jun 16, 2026
Earnings date
RFL Q3 2026 Earnings Scheduled — 2026-06-16
Jun 11, 2026
Earnings
Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results
NEWARK, N.J., June 11, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the third quarter fiscal…
Jun 10, 2026
FDA
Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C
Topline results are expected to be announced in second half of calendar 2026

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Sep 21, 2026
Polinsky David
Chief Financial Officer
TAX W/H$4.1K
Jul 29, 2026
JONAS HOWARD S
Exec Chairman, CEO & President
AWARD$150.0K
Jun 21, 2026
Polinsky David
Chief Financial Officer
TAX W/H$6.3K
Jun 13, 2026
JONAS HOWARD S
Exec Chairman, CEO & President
TAX W/H$20.5K
Jun 13, 2026
JONAS HOWARD S
Exec Chairman, CEO & President
AWARD$250.0K
Mar 21, 2026
Polinsky David
Chief Financial Officer
TAX W/H$3.0K
Mar 13, 2026
JONAS HOWARD S
Exec Chairman, CEO & President
TAX W/H$14.8K
Jan 28, 2026
Sieger Markus
Director
AWARD$37.5K

Earnings setup

Estimates
Nov 2
reports in 7 days
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 15, 2026 Other
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFL
NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
Sep 30, 2026 SEC
Rafael Holdings announced topline results from its pivotal Phase 3 TransportNPC study of Trappsol Cyclo in…
8-K — Impact 7/10
Sep 30, 2026 Press
Rafael Holdings announced topline Phase 3 results for Trappsol Cyclo in Niemann-Pick Disease Type C. The primary…
Impact 7/10
Sep 21, 2026 Insider
Polinsky David surrendered for taxes 2,027 shares
Chief Financial Officer @ $2.03 ($4.1K)
Aug 18, 2026 SEC
Five institutional investors significantly increased positions in Rafael Holdings in Q2 2026, led by Citadel (+364%)…
INST-CLUSTER — Impact 6/10
Jul 29, 2026 Insider
JONAS HOWARD S was granted 54,945 shares
Exec Chairman, CEO & President @ $2.73 ($150.0K)
Jun 30, 2026 Inst.
STATE STREET CORP — DOUBLED
157,270 shares ($515.8K)
Jun 30, 2026 Inst.
KAHN BROTHERS GROUP INC — DOUBLED
150,493 shares ($493.6K)

Washington

Q3 2026
Lobbying Q3 None no reports
YoY n/a vs Q3 2025
Members 0 all time
Buys / sells 0 / 0 0 trades
Open in Washington ›

SecBot reports

5 filings · 3 press releases · 1 bullish · 0 bearish · 2 mixed · 2 neutral
All RFL filing & press-release reports (8)